1. Can dynamic susceptibility contrast magnetic resonance imaging replace single-photon emission computed tomography in the diagnosis of patients with alzheimer's disease? a pilot study
- Author
-
E. L. Engman, P. Julin, Anne-Rita Øksengård, Leif Svensson, Lena Cavallin, Kristoffersen M. Wiberg, Rimma Danielsson, Lars-Olof Wahlund, and A. Frank
- Subjects
Male ,medicine.medical_specialty ,Contrast Media ,Pilot Projects ,Single-photon emission computed tomography ,Gadobutrol ,Central nervous system disease ,Alzheimer Disease ,medicine ,Humans ,Dementia ,Radiology, Nuclear Medicine and imaging ,Aged ,Tomography, Emission-Computed, Single-Photon ,Radiological and Ultrasound Technology ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Female ,Radiology ,Alzheimer's disease ,business ,Nuclear medicine ,Perfusion ,Emission computed tomography ,medicine.drug - Abstract
Purpose: To compare single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) in a cohort of patients examined for suspected dementia, including patients with no objective cognitive impairment (control group), mild cognitive impairment (MCI), and Alzheimer's disease (AD). Material and Methods: Twenty-four patients, eight with AD, 10 with MCI, and six controls were investigated with SPECT using 99mTc-hexamethylpropyleneamine oxime (HMPAO) and dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) with gadobutrol. Three observers performed a visual interpretation of the SPECT and MR images using a four-point visual scale. Results: SPECT was superior to DSC-MRI in differentiating normal from pathological. All three observers showed statistically significant results in discriminating between the control group, AD, and MCI by SPECT, with a P value of 0.0006, 0.04, and 0.01 for each observer. The statistical results were not significant for MR ( P values 0.8, 0.1, and 0.2, respectively). Conclusion: DSC-MRI could not replace SPECT in the diagnosis of patients with Alzheimer's disease. Several patient- and method-related improvements should be made before this method can be recommended for clinical practice.
- Published
- 2006
- Full Text
- View/download PDF